C4X Discovery and Sanofi ink €414m IL-17...C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17...C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17...C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17...C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17...C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17...C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17...C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17...C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
C4X Discovery and Sanofi ink €414m IL-17...C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi. more ➔
Next-gen COVID-19 vaccine good in preclini...Intravacc has announced positive data for its nasal SARS-CoV-2 vaccine that embeds the viral spike antigen in bacterial Outer Membrane Vesicles (OMV) more ➔